

Proposal for the RAS Initiative Review Process

FNLAC charged with overseeing the development and execution of “national cancer research projects” centered at the FNLCR of which the RAS Initiative is the first.

The overarching goal of the Initiative, which started in October of 2013, is to develop therapeutic strategies for the treatment of human cancers driven by mutated RAS.

Progress has been monitored through:

1. A RAS Working Group chaired by Dr. Levi Garraway, meets annually in person and on quarterly teleconferences
2. FNLAC meetings, twice yearly the FNL leadership of the RAS Initiative gives a scientific presentation and Dr. Garraway gives feedback on progress

Review Plan

Goal is to determine whether funding for the Initiative should be extended for 5 more years.

FNLAC Evaluation Team will consist of the current FNLAC members with *ad hoc* reviewers as needed from the research community and private sector.

Review based on:

1. A written report from the RAS Initiative Team
2. Oral presentations by the RAS Initiative leadership to the Evaluation Team
3. A formal recommendation report from the RAS Working Group

The evaluation will be weighted with 80% focused on the progress during this first period and 20% on future plans.

RAS Initiative Report and Site Visit

Report components:

1. An overview to include initial concept and goals, an assessment of progress (both successes and failures and a description of the accomplishments and rationale for closing any projects (12 page limit)
2. For active research projects, a summary of work and a realistic assessment of a future path to clinical application (12 page limit, each project)
3. An overview and assessment of interactions with the RAS research community (academia and industry) to include reagents and resources provided by the RAS Initiative (12 page limit)
4. A discussion of future plans including any change in focus (12 page limit)

Site visit: *The FNLAC evaluation team will meet for one day on November 16, 2016 in Frederick, MD to hear a series of presentations by the leadership of the RAS Initiative.*

Working Group Report

The findings of the Working Group will be important information for the FNLAC evaluation as well as to provide insight into any lessons learned for future development of new initiatives.

--No longer than 5 pages

--Covers their summary of progress, a recommendation to the FNLAC Evaluation Team, and will include:

1. Comments on the scientific goals, direction, priorities, and timelines of the RAS research projects at the FNLAC
2. The extent to which the RAS Initiative engaged academia and industry through collaboration (includes interaction with the RAS Synthetic Lethal Network), sharing ideas, data, and reagents

Important Dates

- Mid Aug. 2016 Last meeting of the Working Group before the review
- Oct. 11, 2016 Written report from the RAS Initiative is due
- Oct. 31, 2016 Written report from the RAS Working Group is due
- Nov. 16, 2016 Site Visit for FNLAC Evaluation Team at Frederick, MD
- Nov. 17, 2016 Oral report from the FNLAC Evaluation Team given to the NCI Director
- Dec. 1, 2016 Formal Recommendation from the FNLAC Evaluation Team sent to the NCI Director
- Dec. 2, 2016 Results of the review shared with the RAS Initiative
- Dec. 5, 2016 Results of the review shared at the joint BSA/NCAB meeting